IMR Press / FBL / Volume 25 / Issue 3 / DOI: 10.2741/4815

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Article
Lonicerin prevents inflammation and apoptosis in LPS-induced acute lung injury
Show Less
1 Department of Emergency, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, Jiangsu 223300, P.R. China
Send correspondence to: Li-Zhi Gu, Department of Emergency, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, 6 Beijing Road West, Huai’an, Jiangsu 223300, P.R. China, Tel: 0517-84907287, Fax: 0517-84907287, E-mail: glzhayy@sina.com
Front. Biosci. (Landmark Ed) 2020, 25(3), 480–497; https://doi.org/10.2741/4815
Published: 1 January 2020
(This article belongs to the Special Issue Leader sequences of coronavirus are altered during infection)
Abstract

Acute lung injury (ALI) is a life-threatening condition caused by severe inflammation of lung tissues. We hypothesized that lipopolysaccharide induced acute lung inflammation and injury in mice might be controlled by lonicerin (LCR), a plant flavonoid that impacts immunity, oxidative stress, and cell proliferation. LCR reduced pathological changes including pulmonary edema, elevation of protein in bronchoalveolar lavage, inflammation, pro-inflammatory gene expression, expression of toll-like receptor 4/nuclear factor-kappa B, apoptosis, and significantly reduced mortality. Together, the results suggest that LCR might be a potential and effective candidate for the treatment of ALI that acts by inhibiting inflammation and apoptosis.

Keywords
Acute lung injury
ALI
Lonicerin
LCR
lipopolysaccharide
LPS
Inflammation
Apoptosis
Figures
Figure 1
Share
Back to top